ReviewEuropean thyroid journal2026
Management of thyroid emergencies: joint consensus statement on management of thyroid storm.
Review in European thyroid journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid storm is a rare but life-threatening endocrine emergency characterised by extreme thyrotoxicosis and multi-organ dysfunction. Prompt recognition and rapid, coordinated management are essential to reduce its high mortality. This consensus statement, developed by experts in endocrinology and acute care, provides practical recommendations for the diagnosis and treatment of thyroid storm. Diagnosis remains clinical, aided by validated scoring systems such as the Burch-Wartofsky and Japanese Thyroid Association/Japan Endocrine Society criteria, which also predict outcomes. Management requires a multidisciplinary approach in high-dependency or intensive care settings, incorporating supportive measures, aggressive treatment of precipitating factors, and targeted therapies. Core treatments include beta-blockade, high-dose antithyroid drugs, corticosteroids, and iodide, with careful attention to timing and contraindications. Adjunctive therapies, such as cholestyramine, lithium, plasmapheresis, and extracorporeal membrane oxygenation (ECMO), as well as surgical thyroidectomy in selected cases, may be required for refractory disease. This guidance also highlights the need for definitive management of underlying hyperthyroidism after stabilisation. By summarising current evidence and expert consensus, this document aims to standardise care, support clinical decision-making, and improve outcomes in patients presenting with thyroid storm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.